Induction of mucosal immune responses against a heterologous antigen fused to filamentous hemagglutinin after intranasal immunization with recombinant Bordetella pertussis.
Live vaccine vectors are usually very effective and generally elicit immune responses of higher magnitude and longer duration than nonliving vectors. Consequently, much attention has been turned to the engineering of oral pathogens for the delivery of foreign antigens to the gut-associated lymphoid tissues. However, no bacterial vector has yet been designed to specifically take advantage of the nasal route of mucosal vaccination. Herein we describe a genetic system for the expression of heterologous antigens fused to the filamentous hemagglutinin (FHA) in Bordetella pertussis. The Schistosoma mansoni glutathione S-transferase (Sm28GST) fused to FHA was detected at the cell surface and in the culture supernatants of recombinant B. pertussis. The mouse colonization capacity and autoagglutination of the recombinant microorganism were indistinguishable from those of the wild-type strain. In addition, and in contrast to the wild-type strain, a single intranasal administration of the recombinant strain induced both IgA and IgG antibodies against Sm28GST and against FHA in the bronchoalveolar lavage fluids. No anti-Sm28GST antibodies were detected in the serum, strongly suggesting that the observed immune response was of mucosal origin. This demonstrates, to our knowledge, for the first time that recombinant respiratory pathogens can induce mucosal immune responses against heterologous antigens, and this may constitute a first step toward the development of combined live vaccines administrable via the respiratory route.
Renauld-Mongénie
G
G
Centre d'Immunologie et de Biologie Parasitaire Institut National de la Santé et de la Recherche Médicale U167, Lille, France.
Mielcarek
N
N
Cornette
J
J
Schacht
A M
AM
Capron
A
A
Riveau
G
G
Locht
C
C
D018829:Adhesins, Bacterial / Q000096:biosynthesis / Q000276:immunology*; D000281:Administration, Intranasal; D000818:Animals; D000907:Antibodies, Bacterial / Q000096:biosynthesis; D000917:Antibody Formation; D000942:Antigens, Bacterial / Q000096:biosynthesis / Q000276:immunology; D000947:Antigens, Helminth; D001428:Bacterial Vaccines / Q000008:administration & dosage; D001483:Base Sequence; D001886:Bordetella pertussis / Q000235:genetics / Q000276:immunology*; D001992:Bronchoalveolar Lavage Fluid / Q000276:immunology*; D017931:DNA Primers; D005838:Genotype; D005982:Glutathione Transferase / Q000276:immunology; D006388:Hemagglutinins / Q000096:biosynthesis / Q000276:immunology*; D007070:Immunoglobulin A / Q000096:biosynthesis; D007074:Immunoglobulin G / Q000096:biosynthesis; D051379:Mice; D008969:Molecular Sequence Data; D009092:Mucous Membrane / Q000276:immunology; D016297:Mutagenesis, Site-Directed; D010641:Phenotype; D016133:Polymerase Chain Reaction; D011995:Recombination, Genetic; D012550:Schistosoma mansoni / Q000201:enzymology; D014614:Vaccines, Synthetic / Q000008:administration & dosage; D010566:Virulence Factors, Bordetella
D018829:Adhesins, Bacterial; D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D000947:Antigens, Helminth; D001428:Bacterial Vaccines; D017931:DNA Primers; D006388:Hemagglutinins; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D014614:Vaccines, Synthetic; D010566:Virulence Factors, Bordetella; C065273:filamentous hemagglutinin adhesin, Bordetella pertussis; D005982:Glutathione Transferase